Dr. Reddy’s Laboratories announces the launch of AlbendazoleTablets, USPin the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Albendazole Tablets, USP,a therapeutic equivalent generic version ofAlbenza Tablets, 200mg,approved by the U.S. Food and Drug Administration (USFDA).

The Albenzabrand and generic had U.S. sales of approximately $27 million MAT for the most recent twelve months ending in November 2020 according to IQVIA Health*.

Dr. Reddy’s Albendazole Tablets, USPareavailable in 200mgtabletsin bottle count sizes of two.

Albenza is a trademark of Glaxosmithkline

Please see the full prescribing information.

https://www.drreddys.com/pil/Albendazole-200mg-Outsert-v_2.pdf

*IQVIA National Sales Perspective: Retail and Non-Retail MAT November2020

RDY-0221-331